Upstream Bio surges 12% on Phase 3 asthma strategy
Strong cash position of $341.5M supports development through 2027 as company targets $40B asthma market with TSLP inhibitor
Upstream Bio shares jumped 12% on Thursday after the clinical-stage biotechnology company outlined a Phase 3 development strategy for its asthma treatment verekitug and reported a cash position sufficient to fund operations into 2027.
The Waltham, Massachusetts-based company, which reported positive Phase 2 results in February showing a 56% reduction in annualized asthma exacerbation rates, now plans to advance verekitug into late-stage testing with a high-dose quarterly regimen of up to 400mg. The Phase 3 program is scheduled to begin dosing in the first quarter of 2027.
Upstream Bio reported $341.5 million in cash, cash equivalents, and short-term investments as of December 31, 2025. The company said this capital position should support planned operations through 2027, including the Phase 3 trials in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
The stock's rally comes despite a mixed initial reaction to the Phase 2 data in February, when shares initially tumbled as investors assessed the competitive landscape. Thursday's announcement appears to have reassured investors about the company's path forward, with the stock gaining $1.02 to close at $9.47.
Analysts remain broadly bullish on Upstream Bio's prospects. Eight analysts cover the stock, with two rating it a Strong Buy and six rating it a Buy, according to market data. The consensus price target stands at $49.75, representing potential upside of approximately 426% from current levels.
Verekitug is a TSLP (thymic stromal lymphopoietin) receptor antagonist, positioning it to compete in the growing severe asthma treatment market. The global severe asthma market was valued at $24.3 billion in 2025 and is projected to reach $39.96 billion by 2035, according to industry forecasts. TSLP inhibitors specifically represent a nearly $8 billion market opportunity by 2030.
The Phase 2 VALIANT trial enrolled 478 adult patients with severe asthma across multiple dosing regimens. The 100mg dose administered every 12 weeks achieved the primary endpoint with a 56% reduction in annualized asthma exacerbation rate compared to placebo (p<0.0003). A 400mg dose every 24 weeks showed a 39% reduction (p<0.02). Beyond exacerbation rates, verekitug also demonstrated clinically meaningful improvements in lung function and safety consistent with previous studies.
Upstream Bio faces competition from Amgen and AstraZeneca's Tezspire, the first-in-class TSLP inhibitor that targets the TSLP ligand rather than the receptor. Tezspire has established itself as a key treatment for severe asthma, particularly in type-2-high disease, with both companies reporting it as a growth driver.
However, Upstream Bio's strategy centers on differentiating verekitug through a high-dose quarterly regimen that could offer dosing convenience advantages. The company plans to engage with the FDA later in 2026 to finalize the Phase 3 design, targeting broad patient populations without biomarker restrictions.
Several other TSLP inhibitors are in development, including Sanofi's lunsekimib and Uniquity Bio's solrikitug, highlighting the pharmaceutical industry's focus on this inflammatory pathway. Novartis is developing an inhaled anti-TSLP treatment that could offer a more convenient administration route compared to injectable biologics.
Verekitug is also being investigated in an ongoing Phase 2 trial for chronic obstructive pulmonary disease (COPD), potentially expanding its commercial opportunity beyond asthma and CRSwNP.
The company reported a net loss of $42.5 million in the fourth quarter of 2025, primarily driven by increased research and development expenses as the Phase 2 program progressed. With $54 million shares outstanding, Upstream Bio's market capitalization stands at approximately $1.26 billion.
Institutional investors hold 93.3% of the float, while insiders own 14.8% of shares, according to regulatory filings. The stock has traded in a 52-week range of $5.14 to $33.68, reflecting significant volatility typical of clinical-stage biotechnology companies.
The Phase 3 development pathway represents a critical inflection point for Upstream Bio. Success in late-stage trials would position the company to enter a market dominated by established players while offering patients a potentially differentiated treatment option in severe asthma, a condition that affects millions of patients worldwide and contributes significantly to healthcare costs.